Efficacy and safety of intravenous ustekinumab re-induction therapy in crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: week 16 results from the power trial

GASTROENTEROLOGY(2023)

引用 0|浏览13
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要